• Je něco špatně v tomto záznamu ?

One-step nucleic acid amplification vs ultrastaging in the detection of sentinel lymph node metastasis in endometrial cancer patients

J. Kosťun, M. Pešta, J. Sláma, R. Slunéčko, P. Vlasák, J. Bouda, Z. Novotný, O. Topolčan, R. Kučera, V. Kulda, K. Houfková, D. Berezovskiy, A. Bartáková, J. Presl,

. 2019 ; 119 (3) : 361-369. [pub] 20181203

Jazyk angličtina Země Spojené státy americké

Typ dokumentu srovnávací studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012078

BACKGROUND AND OBJECTIVES: Utilisation of the one-step nucleic acid amplification (OSNA) molecular biology method for the detection of the metastatic involvement of sentinel lymph nodes (SLNs) in endometrial cancer (EC) patients. A comparison with histopathological ultrastaging and a description of the clinical consequences. METHODS: Surgically treated EC patients underwent detection of SLNs. Nodes greater than 5 mm were cut into sections 2-mm thick parallel to the short axis of the node. Odd sections were examined according to the OSNA method, while even ones according to an appropriate ultrastaging protocol. Nodes less than or equal to 5 mm were cut into halves along the longitudinal axis with one half examined according to the OSNA method and the other half by ultrastaging. RESULTS: Fifty-eight patients were included and 135 SLNs were acquired. Both ultrastaging and OSNA agreed on 116 results. According to the OSNA method, 20.69% more patients were classified into International Federation of Gynecology and Obstetrics (FIGO) stage III. When comparing the results of the OSNA method to the conclusions of ultrastaging as a reference method, sensitivity of 90.9%, specificity of 85.5% and concordance of 85.9% were attained. CONCLUSIONS: The results of the OSNA method showed a higher frequency of detection of micrometastases and included 20.69% more patients into FIGO stage III.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012078
003      
CZ-PrNML
005      
20190606082647.0
007      
ta
008      
190405s2019 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1002/jso.25322 $2 doi
035    __
$a (PubMed)30508294
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Kosťun, Jan, $d 1983- $7 xx0234946 $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic.
245    10
$a One-step nucleic acid amplification vs ultrastaging in the detection of sentinel lymph node metastasis in endometrial cancer patients / $c J. Kosťun, M. Pešta, J. Sláma, R. Slunéčko, P. Vlasák, J. Bouda, Z. Novotný, O. Topolčan, R. Kučera, V. Kulda, K. Houfková, D. Berezovskiy, A. Bartáková, J. Presl,
520    9_
$a BACKGROUND AND OBJECTIVES: Utilisation of the one-step nucleic acid amplification (OSNA) molecular biology method for the detection of the metastatic involvement of sentinel lymph nodes (SLNs) in endometrial cancer (EC) patients. A comparison with histopathological ultrastaging and a description of the clinical consequences. METHODS: Surgically treated EC patients underwent detection of SLNs. Nodes greater than 5 mm were cut into sections 2-mm thick parallel to the short axis of the node. Odd sections were examined according to the OSNA method, while even ones according to an appropriate ultrastaging protocol. Nodes less than or equal to 5 mm were cut into halves along the longitudinal axis with one half examined according to the OSNA method and the other half by ultrastaging. RESULTS: Fifty-eight patients were included and 135 SLNs were acquired. Both ultrastaging and OSNA agreed on 116 results. According to the OSNA method, 20.69% more patients were classified into International Federation of Gynecology and Obstetrics (FIGO) stage III. When comparing the results of the OSNA method to the conclusions of ultrastaging as a reference method, sensitivity of 90.9%, specificity of 85.5% and concordance of 85.9% were attained. CONCLUSIONS: The results of the OSNA method showed a higher frequency of detection of micrometastases and included 20.69% more patients into FIGO stage III.
650    _2
$a adenokarcinom z jasných buněk $x genetika $x sekundární $x chirurgie $7 D018262
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a nádorové biomarkery $x genetika $7 D014408
650    _2
$a serózní cystadenokarcinom $x genetika $x sekundární $x chirurgie $7 D018284
650    _2
$a nádory endometria $x genetika $x patologie $x chirurgie $7 D016889
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a následné studie $7 D005500
650    _2
$a lidé $7 D006801
650    _2
$a peroperační doba $7 D007432
650    _2
$a keratin-19 $x genetika $7 D053539
650    _2
$a lymfatické metastázy $7 D008207
650    _2
$a lidé středního věku $7 D008875
650    _2
$a mikrometastázy $7 D061206
650    _2
$a techniky amplifikace nukleových kyselin $x metody $7 D021141
650    _2
$a nukleové kyseliny $x analýza $x genetika $7 D009696
650    _2
$a prognóza $7 D011379
650    _2
$a sentinelová uzlina $x patologie $x chirurgie $7 D000071036
650    _2
$a biopsie sentinelové lymfatické uzliny $7 D021701
650    _2
$a míra přežití $7 D015996
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
700    1_
$a Pešta, Martin $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. Biomedical Centre, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic. Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Sláma, Jiří $u Department of Obstetrics and Gynaecology, First Faculty of Medicine, Charles University, General University Hospital, Prague, Czech Republic.
700    1_
$a Slunečko, Robert $7 xx0236829 $u Sikl's Department of Pathology, University Hospital Pilsen, Charles University, Prague, Czech Republic.
700    1_
$a Vlasák, Pavel $7 xx0234945 $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic.
700    1_
$a Bouda, Jiří $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic.
700    1_
$a Novotný, Zdeněk $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic.
700    1_
$a Topolčan, Ondřej $u Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Kučera, Radek $u Department of Immunochemistry, University Hospital and Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Kulda, Vlastimil $u Department of Medical Chemistry and Biochemistry, Faculty of Medicine in Pilsen, Charles University, Prague, Czech Republic.
700    1_
$a Houfková, Kateřina $u Department of Biology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic.
700    1_
$a Berezovskiy, Denis $7 xx0234948 $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic.
700    1_
$a Bartáková, Alena $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic.
700    1_
$a Presl, Jiří $7 xx0234942 $u Department of Gynaecology and Obstetrics, University Hospital Pilsen, Charles University, Prague, Czech Republic.
773    0_
$w MED00010662 $t Journal of surgical oncology $x 1096-9098 $g Roč. 119, č. 3 (2019), s. 361-369
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30508294 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190606082824 $b ABA008
999    __
$a ok $b bmc $g 1391388 $s 1050383
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 119 $c 3 $d 361-369 $e 20181203 $i 1096-9098 $m Journal of surgical oncology $n J Surg Oncol $x MED00010662
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Možnosti archivace